These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Empagliflozin for the treatment of Type 2 diabetes. Gangadharan Komala M; Mather A Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488 [TBL] [Abstract][Full Text] [Related]
13. ▼ Apremilast for psoriasis and psoriatic arthritis. Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317 [TBL] [Abstract][Full Text] [Related]
14. Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer. Sezer H; Yazıcı D; Deyneli O; Meriçöz Ç; Esin A; Alper E Endokrynol Pol; 2020; 71(3):283-284. PubMed ID: 32154575 [TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks. Erskine D Drug Ther Bull; 2020 Mar; 58(3):34. PubMed ID: 32102786 [No Abstract] [Full Text] [Related]
16. Empagliflozin in diabetes: A therapeutic light at the end of the cardiovascular tunnel? Grant PJ Diab Vasc Dis Res; 2015 Nov; 12(6):394-5. PubMed ID: 26493599 [No Abstract] [Full Text] [Related]
17. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. Anker SD; Ponikowski P; Wanner C; Pfarr E; Hauske S; Peil B; Salsali A; Ritter I; Koitka-Weber A; Brueckmann M; Lindenfeld J; Abraham WT; Circulation; 2021 Oct; 144(15):1265-1267. PubMed ID: 34397263 [No Abstract] [Full Text] [Related]
18. SGLT2 inhibitors: new reports. Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203 [TBL] [Abstract][Full Text] [Related]
19. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269 [TBL] [Abstract][Full Text] [Related]